Loading
TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription.
Open Targets scores its association with cancer at 0.80 (direct and indirect evidence; datatypes affected pathway 0.40, literature 0.98, genetic association 0.72, somatic mutation 0.83, animal model 0.75). IntOGen calls it a driver in 5 cohorts (1 activating, 4 loss-of-function), covering Bladder Urothelial Carcinoma, Cervical Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma, Melanoma, Neuroblastoma.
In plain words · TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.
TP63 (Tumour protein 63) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Skin cancer, Non-Hodgkin lymphoma and 5 more.
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity.
No product in this corpus aims at TP63 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
First described 1998. Earliest sequence paper UniProt cites for the protein: Senoo et al, Biochem. Biophys. Res. Commun, 1998, "A second p53-related protein, p73L, with high homology to p73". Source.
Sources: HGNC HGNC:15979 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q9H3D4 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000073282 (association with cancer (MONDO_0004992) 0.80; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.63, melanoma 0.60, non-Hodgkin lymphoma 0.64, skin cancer 0.68, basal cell carcinoma 0.52, breast cancer 0.56 (GraphQL API, CC0)); IntOGen TP63 (driver in 5 cohorts (Act 1, LoF 4); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signalling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. Location: Nucleus (UniProt). Locus 3q28 (HGNC).
Query for this target: (TITLE:"TP63" OR ABSTRACT:"TP63" OR TITLE:"tumor protein p63" OR ABSTRACT:"tumor protein p63" OR TITLE:"Tumor protein 63" OR ABSTRACT:"Tumor protein 63" OR TITLE:"p51" OR ABSTRACT:"p51" OR TITLE:"SHFM4" OR ABSTRACT:"SHFM4" OR TITLE:"EEC3" OR ABSTRACT:"EEC3") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about TP63, not a curated reading list.
Shares Leukaemia (all types), Cervical cancer, IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Bladder & urothelial cancer, IntOGen, Head and neck squamous cell carcinoma.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Head and neck squamous cell carcinoma.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Breast cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Cervical cancer, Bladder & urothelial cancer, IntOGen.
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).
Shares Leukaemia (all types), Skin cancer (all types), IntOGen, Lung cancer (all types).